Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Oct 23, 2017 |
signed chap.357 |
Oct 11, 2017 |
delivered to governor |
Jun 21, 2017 |
returned to assembly passed senate 3rd reading cal.2161 substituted for s4788a |
Jun 21, 2017 |
substituted by a7509a ordered to third reading cal.2161 committee discharged and committed to rules |
Jun 16, 2017 |
print number 4788a |
Jun 16, 2017 |
amend (t) and recommit to higher education |
Mar 01, 2017 |
referred to higher education |
Senate Bill S4788
Signed By Governor2017-2018 Legislative Session
Sponsored By
(R, C, IP) Senate District
Archive: Last Bill Status Via A7509 - Signed by Governor
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Votes
Bill Amendments
co-Sponsors
(R, C, IP) Senate District
(R, C) 53rd Senate District
(R, C, IP) 54th Senate District
(D) Senate District
2017-S4788 - Details
- Law Section:
- Education Law
- Laws Affected:
- Amd §§6802, 6810 & 6816-a, Ed L; amd §206, Pub Health L
2017-S4788 - Sponsor Memo
BILL NUMBER: S4788 TITLE OF BILL : An act to amend the education law and the public health law, in relation to the substitution of interchangeable biological products for prescribed products PURPOSE : This bill would establish requirements for pharmacies to substitute and dispense biological products. SUMMARY OF PROVISIONS : Section 1 amends section 6802 of the education law to add the definition of biological product as defined in subsection (i) of section 351 of the Public Health Service Act 42 U.S.C. Section 262(i); and adds the definition of interchangeable biologic product as defined pursuant to 42 U.S.C. Section 262(k)(4) or as determined by the FDA to be therapeutically equivalent. Sections 2 and 3 amend sections 6810 and 6816-a of the education law to extend notification to the patient by the prescriber regarding the product prescribed to include an interchangeable biological product, as is existing practice with a brand name or its generic equivalent drug product and suspends the requirement that a pharmacist substitute a biologic product when an interchangeable biological substitute is
2017-S4788 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4788 2017-2018 Regular Sessions I N S E N A T E March 1, 2017 ___________ Introduced by Sen. HANNON -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education AN ACT to amend the education law and the public health law, in relation to the substitution of interchangeable biological products for prescribed products THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Section 6802 of the education law is amended by adding two new subdivisions 27 and 28 to read as follows: 27. "BIOLOGICAL PRODUCT" MEANS A BIOLOGICAL PRODUCT AS DEFINED IN SUBSECTION (I) OF SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT, 42 U.S.C. SECTION 262(I). 28. "INTERCHANGEABLE BIOLOGICAL PRODUCT" MEANS A BIOLOGICAL PRODUCT LICENSED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION PURSUANT TO 42 U.S.C. SECTION 262(K)(4) AS SET FORTH IN THE LATEST EDITION OR SUPPLEMENT OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION LISTS OF LICENSED BIOLOGICAL PRODUCTS WITH REFERENCE PRODUCT EXCLUSIVITY AND BIOSIMILARITY OR INTERCHANGEABILITY EVALUATIONS, SOMETIMES REFERRED TO AS THE "PURPLE BOOK," OR A BIOLOGICAL PRODUCT DETERMINED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION TO BE THERAPEUTICALLY EQUIVALENT AS SET FORTH IN THE LATEST EDITION OR SUPPLEMENT OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIV- ALENCE EVALUATIONS, SOMETIMES REFERRED TO AS THE "ORANGE BOOK." § 2. Paragraphs (b), (c) and (d) of subdivision 6 of section 6810 of the education law, paragraph (b) as amended and paragraph (d) as added by chapter 913 of the laws of 1986, paragraph (c) as added by chapter 776 of the laws of 1977, are amended to read as follows: (b) NOTWITHSTANDING ANY OTHER PROVISION OF THIS SECTION OR ANY OTHER LAW, WHEN AN INTERCHANGEABLE BIOLOGICAL PRODUCT IS NOT AVAILABLE AND THE BIOLOGICAL PRODUCT ORIGINALLY PRESCRIBED IS AVAILABLE AND THE PHARMACIST AGREES TO DISPENSE THE PRESCRIBED BIOLOGICAL PRODUCT FOR A PRICE THAT EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
co-Sponsors
(R, C, IP) Senate District
(R, C) 53rd Senate District
(R, C, IP) 54th Senate District
(D, IP) Senate District
2017-S4788A (ACTIVE) - Details
- Law Section:
- Education Law
- Laws Affected:
- Amd §§6802, 6810 & 6816-a, Ed L; amd §206, Pub Health L
2017-S4788A (ACTIVE) - Sponsor Memo
BILL NUMBER: S4788A TITLE OF BILL : An act to amend the education law and the public health law, in relation to the substitution of interchangeable biological products for prescribed products; and providing for the expiration of such provisions PURPOSE : This bill would establish requirements for pharmacies to substitute and dispense biological products. SUMMARY OF PROVISIONS : Section 1 amends section 6802 of the education law to add the definition of biological product as defined in subsection (i) of section 351 of the Public Health Service Act 42 U.S.C. Section 262(i); and adds the definition of interchangeable biologic product as defined pursuant to 42 U.S.C. Section 262(k)(4) or as determined by the FDA to be therapeutically equivalent. Sections 2 and 3 amend sections 6810 and 6816-a of the education law to extend notification to the patient by the prescriber regarding the product prescribed to include an interchangeable biological product, as is existing practice with a brand name or its generic equivalent drug product and suspends the requirement that a pharmacist substitute
2017-S4788A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4788--A 2017-2018 Regular Sessions I N S E N A T E March 1, 2017 ___________ Introduced by Sens. HANNON, DeFRANCISCO, GRIFFO, HELMING, LATIMER, VALE- SKY -- read twice and ordered printed, and when printed to be commit- ted to the Committee on Higher Education -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said commit- tee AN ACT to amend the education law and the public health law, in relation to the substitution of interchangeable biological products for prescribed products; and providing for the expiration of such provisions THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Section 6802 of the education law is amended by adding two new subdivisions 27 and 28 to read as follows: 27. "BIOLOGICAL PRODUCT" MEANS A BIOLOGICAL PRODUCT AS DEFINED IN SUBSECTION (I) OF SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT, 42 U.S.C. SECTION 262(I). 28. "INTERCHANGEABLE BIOLOGICAL PRODUCT" MEANS A BIOLOGICAL PRODUCT LICENSED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION PURSUANT TO 42 U.S.C. SECTION 262(K)(4) AS SET FORTH IN THE LATEST EDITION OR SUPPLEMENT OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION LISTS OF LICENSED BIOLOGICAL PRODUCTS WITH REFERENCE PRODUCT EXCLUSIVITY AND BIOSIMILARITY OR INTERCHANGEABILITY EVALUATIONS, SOMETIMES REFERRED TO AS THE "PURPLE BOOK," OR A BIOLOGICAL PRODUCT DETERMINED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION TO BE THERAPEUTICALLY EQUIVALENT AS SET FORTH IN THE LATEST EDITION OR SUPPLEMENT OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIV- ALENCE EVALUATIONS, SOMETIMES REFERRED TO AS THE "ORANGE BOOK." § 2. Paragraphs (b), (c) and (d) of subdivision 6 of section 6810 of the education law, paragraph (b) as amended and paragraph (d) as added by chapter 913 of the laws of 1986, paragraph (c) as added by chapter 776 of the laws of 1977, are amended to read as follows: EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.